<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02799771</url>
  </required_header>
  <id_info>
    <org_study_id>GERMOP- 005</org_study_id>
    <nct_id>NCT02799771</nct_id>
  </id_info>
  <brief_title>HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION</brief_title>
  <acronym>HYPID-2</acronym>
  <official_title>Observational Study of Incident Patients With Pre Capillary Pulmonary Hypertension and Interstitial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HYPID-2 study is an extension of HYPID study (NCT01443598) :

      HYPID-2 is also an observational and prospective study of patients with interstitial lung
      disease and pre capillary hypertension diagnosed by right heart sided catheterization.

      It concerns only incident patients (i.e patients included within 6 months after PH diagnosis)
      whereas HYPID concerned prevalent and incident cases.

      The primary aim is the same than HYPID : identify prognostic factors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre capillary pulmonary hypertension (PH) may be present in patients with diffuse
      interstitial lung disease.

      In this context, PH represents an important factor of morbidity and mortality for these
      patients.

      As in HYPID, the main purpose of HYPID-2 is to determine predictive factors of mortality
      within this cohort of incident patients (i.e patients included within 6 months after PH
      diagnosis).

      In order to reach that aim,the study includes an evaluation based on exams conducted for the
      routine follow-up of incident patients.

      Each incident patient will be followed during 2 years at least.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Determine predictive factors of mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time to death or 10% decline in FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to therapy</measure>
    <time_frame>2 years</time_frame>
    <description>Proposition of patients with 10% or more decline in PVR</description>
  </secondary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>Diffuse Interstitial Lung Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Incident patients with pre capillary pulmonary hypertension and interstitial lung disease
        at HRCT
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients newly diagnosed with:

          -  Pre capillary pulmonary hypertension at right heart sided catheterization with: mPAP &gt;
             or = 25 mmHg, PCWP &lt; or = 15 mmHg

          -  Interstitial lung disease with diffuse infiltrative opacities on chest CT scan

        Exclusion Criteria:

          -  Pulmonary hypertension related to a thromboembolic disease

          -  Respiratory disease other than diffuse interstitial lung disease

          -  Any etiological factor of pulmonary arterial hypertension based on NICE 2013
             classification other than diffuse interstitial lung disease

          -  Any progressive disease associated to a life expectancy less than 6 months other than
             pulmonary hypertension, diffuse interstitial lung disease and respiratory
             insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent COTTIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices civils de Lyon / Université Lyon I</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Louis Pradel Hospital (Bâtiment A4)</name>
      <address>
        <city>Lyon</city>
        <state>Bron</state>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://maladies-pulmonaires-rares.fr/</url>
    <description>website National French Reference Center for rare lung diseases</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2016</study_first_submitted>
  <study_first_submitted_qc>June 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires</investigator_affiliation>
    <investigator_full_name>Vincent COTTIN</investigator_full_name>
    <investigator_title>Professor Vincent COTTIN</investigator_title>
  </responsible_party>
  <keyword>Pulmonary arterial hypertension</keyword>
  <keyword>Interstitial lung disease at HRCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

